This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Hits Targets, Backs '09 Forecast

Updated from 8:48 a.m. EST

Abbott Laboratories (ABT - Get Report) matched Wall Street's fourth-quarter earnings estimates Wednesday and reiterated its forecast for double-digit profit growth in 2009.

The diagnostics, medical devices and drug maker reported net income for the fourth quarter of $1.54 billion, or 98 cents a share, compared with net income of $1.2 billion, or 77 cents a share, in the year-ago quarter.

Excluding special items, Abbott reported a 14% increase in earnings per share to $1.06 in the fourth quarter, in line with the Street's consensus estimate.

Fourth-quarter revenue rose 10% to $7.95 billion, essentially matching the consensus analyst forecast of $8 billion. Abbott reported revenue of $7.22 billion in the year-ago quarter.

Abbott reiterated its 2009 earnings forecast, first offered Jan. 12, in the range of $3.65 to $3.70 a share on both a GAAP and adjusted basis. At the time, Wall Street was expecting earnings of $3.66 a share.

The midpoint of Abbott's guidance represents 10% growth over 2008 adjusted earnings of $3.32 a share.

Abbott's 2009 earnings outlook includes the company's planned $2.8 billion purchase of eye care company Advanced Medical Optics (EYE).

The bullish forecast offered by Abbott management stands in contrast with diversified health care giant Johnson & Johnson (JNJ - Get Report), which said Tuesday that this year's revenue would fall from the reported 2008 level, the company's first annual revenue decline in 75 years. Johnson & Johnson blamed the recession, which is forcing consumers to spend less on health care products, both prescription drugs and consumer products.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $37.21 0.00%
JNJ $101.73 0.00%
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs